Dedicated to every detail that drives CAR T success

Focused on your needs

Developing treatments for patients with cancer and autoimmune disease

Corporate presentations

Clinical-stage programs for hematological and solid tumor indications as well as autoimmune diseases

Transforming treatments for adult Acute Lymphoblastic Leukemia

Our products
1/4

Who we are

Autolus applies extensive programming capabilities to develop advanced autologous T cell therapies that have the potential to deliver life-changing therapies to patients with cancer and autoimmune diseases and is building a fully integrated, next-generation CAR T company

About us

Our Technology

Chimeric Antigen Receptors

We use Chimeric Antigen Receptors (CARs) to reprogram our T cell product candidates. These receptors combine the tumor recognition domain of an antibody with the activation and costimulatory domains from the T cell receptor to rearm a patient’s T cells to recognize and kill their cancer cells.

Advanced Cell Programming

Autolus is applying its extensive cell programming capability to develop a pipeline of precise, controlled and highly active products.

T Cell Manufacturing

We have developed our own proprietary viral vector and semi-automated cell manufacturing processes to engineer a patient's T cells with the CAR and other advanced cell programing modules.

Explore our technology

Abstracts and Publications

See all
New England Journal of Medicine
November 27 2024

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia

Nature Medicine
July 06 2023

Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia

Molecular Therapy
March 21 2023

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR

Latest news

Get the latest updates from Autolus on new research, company news and events

View all news

Information for patients

Clinical trials are required to gain regulatory approval for new medicines to advance patient care.

Learn more about our CAR T cell therapy clinical trials

Life at Autolus

Whilst working at Autolus you will enjoy a flexible, diverse and dynamic working environment which actively promotes creativity, leadership and teamwork – together we are ONE Autolus.

Careers at Autolus

Investors

Autolus is building a fully-integrated, next generation CAR T company. It is committed to the development and commercialization of obe-cel in r/r Adult ALL and is progressing opportunities for obe-cel in additional indications alongside its preclinical and clinical pipeline for hematological malignancies and solid tumors.

View investor information

Breaking news:

Autolus obtains its first FDA approval for a CAR T cell therapy!

Please note that this CAR T cell therapy is not authorized for use outside of the US. If you are a physician based in the US, please visit this website to learn more about our product.

CAR=chimeric antigen receptor; FDA=Food and Drug Administration.

© Autolus, Inc. 2025. Autolus and associated logo are trademarks of Autolus Therapeutics. All Rights Reserved. 11/2024 US-AUC-0005